SAN FRANCISCO, CA, USA (UroToday.com) - Dr. Gary MacVicar challenged the GU Symposium audience to effectively sequence, combine therapies, and target treatments to men with metastatic CRPC.
After years where doxetaxel was the go-to agent, now there are FDA-approved agents to treat mCRPC with strong phase III trial data to support improved survivability (Sipuleucel-T, cabazitaxel, and abiraterone). Radium-223 is demonstrating strong clinical data. Denosumab, an option to delay progression of bone disease in men with M0 CRPC, is a monoclonal antibody agent, and in initial studies has proved to disrupt that vicious cycle of bone targeted therapy and with lower toxicity levels. Dr. MacVicar notes the need to include a calcium supplement with vitamin D for those patients on denosumab.
In all the therapeutic categories (immunotherapy, hormonal therapy, targeted bone therapy, and cytotoxic chemotherapy) more studies are needed to identify how to best sequence or combine these novel agents along with how to select therapies for individual patients or subsets of patients.
| |
|
|
(Months) |
|
|
| TAX 327 | Docetaxel/prednisone vs. mitoxantrone/prednisone | 1,006 | 2.4 | 0.76 | 0.009 |
| IMPACT | Sipuleucel-T vs. placebo | 512 | 4.1 | 0.775 | 0.032 |
| TROPIC | Cabazitaxel/prednisone vs. mitoxantrone/prednisone | 755 | 2.4 | 0.70 | <0.0001 |
| COU 301 | Abiraterone/prednisone vs. placebo/prednisone | 1,195 | 3.9 | 0.65 | < 0.001 |
| ALSYMPCA | Radium-223 vs. placebo | 922 | 2.8 | 0.695 | 0.00185 |
Phase III trials with improvements in overall survival in metastatic castration-resistant prostate cancer
Presented by Gary R. MacVicar, MD at the 2012 Genitourinary Cancers Symposium - February 2 - 4, 2012 - San Francisco Marriott Marquis - San Francisco, California
Northwestern University, Chicago, IL
Reported for UroToday by Karen Roberts, Medical Writer
View Full 2012 GU Cancers Symposium Coverage
